Melinta Therapeutics, Inc.

ACTIVE

6340 Quadrangle Dr Ste 100, 康涅狄格州纽黑文县, 康涅狄格州, United Statesmelinta.comPrivate290 employeesEstablished: 2000-01-01

Clinical Trials

16 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2000

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

44.0%

Phase 3

22.0%

Phase 2

18.0%

Not Applicable

4.0%

Trial Status Distribution

Active, not recruiting

32.0%

Completed

60.0%

Terminated

6.0%

Withdrawn

2.0%

Clinical Trials

Trials sponsored by this organization (50)

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Phase 2

Active, not recruiting

interventional

Jun 202566 participants

A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults

Phase 1

Terminated

interventional

Jun 202416 participants

Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

Phase 1

Completed

interventional

Jul 2019102 participants

A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults

Phase 1

Completed

interventional

Apr 201830 participants

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA

Not Applicable

Completed

interventional

Jul 20174 participants

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

Completed

observational

Apr 2017325 participants

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

Phase 3

Completed

interventional

Dec 2016860 participants

Page 1 of 7

Approvals

No approval data available

News

No news articles found

Back to Organizations